Leora Horn, MD, MSc, FRCPC

December 21, 2020

|

Estimated Read Time:

1–2 minutes

Leora Horn, MD, MSc, FRCPC, has joined AstraZeneca as the Global Head of Lung Cancer Strategy. Prior to joining AstraZeneca in September 2020, Dr. Horn was an Associate Professor of Cancer Research at Vanderbilt Ingram Cancer Center and Associate Professor of Medicine in the Division of Hematology/Oncology at the Vanderbilt University Medical Center.

About the Authors

Share this Article:

Leora Horn, MD, MSc, FRCPC

Recent Posts

ctDNA-Guided Adaptive De-escalation Therapy for Advanced NSCLC: Ready for Prime Time?

AI and the Diagnosis of TETs: Teaching Machines to See What Pathologists See

Timing is of the Essence: Commentary on NRG/Alliance LU005 Results

Successive Versions of the Same Topic: Translating Data From ASCO 2026

COCOON’s Prophylactic Regimen Resulted in Decreased Incidence and Severity of Dermatologic-related Adverse Events

MARIPOSA OS Data Confirms Improved Efficacy for Amivantamab Plus Lazertinib in the First Line for EGFR-mutated NSCLC

Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection

Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy

Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC

No “Known” Risk Factors: The Health Consequences of Radiation Therapy

Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging

No PFS, OS Benefit Seen in Final Results from PACIFIC-2

WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers

Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture

A Holistic Approach to Patient Care